A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed at least 12 Months From Completion of Neoadjuvant/Adjuvant Taxotere- Based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Docetaxel; Doxorubicin
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 29 Jun 2007 New trial record.